Systematic Review And Meta-Analysis Of Psoriasis Treatments.

This study has been completed.
Sponsor:
Collaborator:
University of Connecticut School of Pharmacy and Hartford Hospital
Information provided by (Responsible Party):
Pfizer
ClinicalTrials.gov Identifier:
NCT01425138
First received: August 26, 2011
Last updated: September 28, 2011
Last verified: September 2011
  Purpose

This project involved a systematic literature review of published trials of treatments for moderate-to-severe plaque psoriasis. Data was extracted from the publications on various psoriasis endpoints including the Physician Global Assessment (PGA), Dermatology Life Quality Index (DLQI), and Short-Form 36 (SF-36). A traditional meta-analysis and a mixed treatment comparison was conducted on the extracted data.


Condition
Psoriasis

Study Type: Observational
Study Design: Time Perspective: Retrospective
Official Title: Biologic And Non-biologic Systemic Treatments For Moderate To Severe Plaque Psoriasis: A Systematic Review & Meta-Analysis

Resource links provided by NLM:


Further study details as provided by Pfizer:

Primary Outcome Measures:
  • Physician Global Assessment (PGA) [ Designated as safety issue: No ]
  • Dermatology Life Quality Index (DLQI) [ Designated as safety issue: No ]
  • Short-Form 36 (SF-36) [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • No secondary outcomes [ Time Frame: No secondary outcomes ] [ Designated as safety issue: No ]

Estimated Enrollment: 0
Study Start Date: June 2009
Study Completion Date: June 2011
Primary Completion Date: June 2011 (Final data collection date for primary outcome measure)
Groups/Cohorts
Psoriasis
Published data on moderate-to-severe plaque psoriasis.

Detailed Description:

This project involved a systematic literature review of published trials of treatments for moderate-to-severe plaque psoriasis. Data was extracted from the publications on various psoriasis endpoints including the Physician Global Assessment (PGA), Dermatology Life Quality Index (DLQI), and Short-Form 36 (SF-36). A traditional meta-analysis and a mixed treatment comparison was conducted on the extracted data. We included all published randomized controlled trials of treatments for moderate-to-severe psoriasis that met the study inclusion criteria.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Moderate-to-severe plaque psoriasis published trials.

Criteria

Inclusion Criteria:

  • Randomized controlled clinical trials of treatments for moderate-to-severe plaque psoriasis.
  • Trials had to evaluate at least one of the following: Physician's Global Assessment (PGA), Dermatology Life Quality Index (DLQI) and/or the Short-Form 36 (SF-36).

Exclusion Criteria:

Observational studies

  • Trials that did not report the Physician's Global Assessment (PGA),
  • Dermatology Life Quality Index (DLQI) or the Short-Form 36 (SF-36).
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01425138

Sponsors and Collaborators
Pfizer
University of Connecticut School of Pharmacy and Hartford Hospital
Investigators
Study Director: Pfizer CT.gov Call Center Pfizer
  More Information

Additional Information:
No publications provided

Responsible Party: Pfizer
ClinicalTrials.gov Identifier: NCT01425138     History of Changes
Other Study ID Numbers: A3921142
Study First Received: August 26, 2011
Last Updated: September 28, 2011
Health Authority: Health Authority: None

Keywords provided by Pfizer:
psoriasis
systematic review
meta-analyses

Additional relevant MeSH terms:
Psoriasis
Skin Diseases, Papulosquamous
Skin Diseases

ClinicalTrials.gov processed this record on August 21, 2014